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A novel, somatic, transforming 
mutation in the extracellular 
domain of Epidermal Growth 
Factor Receptor identified in 
myeloproliferative neoplasm
D. A. Casolari1,2, T. Nguyen1,2, C. M. Butcher2,4, D. G. Iarossi1,2, C. N. Hahn  1,3, S. C. Bray1,2,4,5, 
P. Neufing4, W. T. Parker1,3, J. Feng1,3, K. Z. Y. Maung1,2,4,5, A. Wee1,2,4,5, L. Vidovic1,2,  
C. H. Kok6, P. G. Bardy4, S. Branford1,3, I. D. Lewis1,2, S. W. Lane7, H. S. Scott1,3,  
D. M. Ross  2,5,6,8 & R. J. D’Andrea1,2,9
We describe a novel ERBB1/EGFR somatic mutation (p. C329R; c.985 T > C) identified in a patient with 
JAK2V617F Polycythaemia Vera (PV). This substitution affects a conserved cysteine residue in EGFR 
domain 2 and leads to the formation of a ligand-independent covalent receptor dimer, associated 
with increased transforming potential. Aberrant signalling from the EGFRC329R receptor is cell type-
dependent and in the TF1.8 erythroid cell line expression of this mutant suppresses EPO-induced 
differentiation. Clonal analysis shows that the dominant JAK2V617F-positive clone in this PV patient 
harbors EGFRC329R, thus this mutation may contribute to clonal expansion. Somatic mutations affecting 
other ERBB and related receptor tyrosine kinases are observed in myeloproliferative neoplasms (MPN), 
and we show elevated EGFR levels in MPN samples, consistent with previous reports. Thus activation of 
this group of receptors, via multiple mechanisms, may contribute to clonal growth and survival of the 
JAK2V617F disease clone in MPN.
The ErbB receptor family, including epidermal growth factor receptor (ERBB1/EGFR), represents a group of 
receptor tyrosine kinases (RTKs) with established roles in cancer. While the role of this family has not been investi-
gated in detail in haematopoietic malignancies (HM), the activation of RTKs by mutation has a well-characterised 
role in HM; in particular, activating mutations in FLT3 and KIT are well described in acute myeloid leukaemia 
(AML)1. Cancer-associated mutations affecting the E3 Ubiquitin ligase, CBL, which is required for ubiquitination 
and degradation of multiple RTKs, are also recurrent across HM, including the BCR-ABL-negative myelopro-
liferative neoplasms (MPN)2. Increased activity of the receptor-associated tyrosine kinase JAK2 by activating 
mutation (most frequently JAK2V617F) is a feature of this group of MPN, including essential thrombocythaemia 
(ET), Polycythaemia Vera (PV) and Primary Myelofibrosis (PMF)3. Here we describe a novel somatic, transform-
ing, EGFR variant with an extracellular cysteine substitution in domain 2 (EGFRC329R), identified in a PV patient. 
PV is characterized by clonal erythroid hyperplasia and high frequency of JAK2 activating mutations (in >98% 
of cases)3. PV is associated with clinical features including thrombosis, constitutional symptoms, and risk of 
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transformation to myelofibrosis (MF) and AML. Loss of heterozygosity (LOH) for JAK2 occurs frequently in PV 
and is associated with expansion of the erythroid lineage; however, JAK2V617F LOH alone is insufficient to sustain 
disease4. Co-operating mutations may contribute to the disease phenotype. Hence, there is significant interest in 
the contribution of JAK2-independent signalling in MPN, particularly given that the same JAK2 mutation can 
lead to diverse disease phenotypes, and since JAK inhibitor therapy typically does not lead to eradication of the 
MPN clone. Thus, acquisition of additional JAK2-independent events in the MPN clone is presumably important 
for disease.
Our characterization of EGFRC329R shows that the mutation induces ligand-independent covalent receptor 
dimerization and is associated with increased transforming potential. This mechanism of activation is similar to 
that reported for recurrent mutations that affect the extracellular domain of EGFR in glioblastoma, EGFRvIII, as 
well as non-synonymous mutations affecting residues in a conserved cysteine-rich region critical for the forma-
tion of intra-molecular disulphide bonds in domains 2 and 4 of the receptor5, 6. Consistent with a role in clonal 
expansion and MPN pathogenesis, we show that the EGFRC329R mutant leads to loss of erythroid lineage markers, 
and reduced EPO-induced differentiation in an erythroid differentiation model (TF-1.8 human erythroleukaemia 
cell line). A comprehensive survey of somatic mutations affecting ERBB genes, and the genes encoding the related 
RTKs, MET and ALK, shows rare mutations across published MPN cohorts. Thus, we suggest that aberrant acti-
vation of these receptors by mutation is a rare event but likely cooperates with JAK2 signalling to influence the 
growth and lineage properties of the MPN disease clone.
Results and Discussion
Identification of a somatic EGFRC329R mutation in PV. Targeted exon capture and massively parallel 
sequencing of 657 cancer-related genes in peripheral blood mononuclear cells (PBMNC) or granulocyte DNA 
from 15 JAK2V617F-positive PV patients (Suppl. Tables S1 and S2) identified a somatic EGFR variant (p. C329R; 
c.985 T > C) in one patient (PV17) (Suppl. Figure S1a). The screen included genes encoding multiple growth 
factor and cytokine receptors. Additional variants identified are shown in Suppl. Table S3, and include a previ-
ously reported activating variant7 affecting MET, in another PV patient (METY1248H; Suppl. Figure S1a and Suppl. 
Table S5). The human EGFR C329 residue resides in the cysteine-rich region in extracellular domain 2, which 
promotes receptor dimerization (Fig. 1a) and is the target of recurrent somatic mutations in glioblastoma6, 8. 
Moreover, it aligns with the C359 residue of the orthologous C. elegans receptor, let-23, that is the target of a 
known gain-of-function mutation9, and with the cysteine residue affected in the transforming human ERBB2/
HER2 mutation, C334S10.
The EGFRC329R mutant displays oncogenic potential and cell-type specific signalling. We first 
investigated the oncogenic potential of this novel EGFR variant by measuring anchorage-independent growth of 
transduced NIH3T3 cells expressing similar levels of either wild type (WT) EGFR (NIH3T3/EGFR) or EGFRC329R 
(NIH3T3/C329R) (Suppl. Figure S2a). Colony formation in the absence of exogenous EGF was increased in 
NIH3T3/C329R cells compared to NIH3T3/EGFR cells (Fig. 1b and Suppl. Figure S2b, respectively 31 ± 4.9 vs. 
15 ± 1.6, P < 0.05); however, in the presence of EGF (10 ng/mL), colony numbers were similar for both cell pop-
ulations. Several mutations affecting EGFR and ERBB2 extracellular cysteine residues lead to the formation of 
activated dimeric receptor through an intermolecular disulphide bond which involves the remaining free cysteine 
residue5, 10, 11. Based on the receptor modelling (Suppl. Figure S1b) we proposed a similar mechanism of dimeri-
zation and activation for EGFRC329R. We investigated this by western blot using reducing and non-reducing con-
ditions. The presence of the high molecular weight EGFR dimer was observed constitutively under non-reducing 
conditions in NIH3T3/C329R cells, but not in NIH3T3/EGFR cells, and its abundance increased after treatment 
with EGF (10 ng/mL, Fig. 1c and Suppl. Figure S3). The presence of the EGFR dimer correlated with altered sig-
nalling responses. NIH3T3/C329R cells displayed increased levels of phosphorylated p-EGFRTyr1068 compared to 
NIH3T3/EGFR in serum-containing media, and a profound increase of p-ERK1/2Thr202/Tyr204 in both the presence 
and absence of serum (Fig. 1d and Suppl. Figure S4). These data confirm that the C329R domain 2 mutation pro-
motes covalent, ligand-independent receptor dimerization and altered signalling.
We next investigated the effect of the C329R substitution on EGF sensitivity and EGF-induced growth and 
survival of transduced haematopoietic BaF3 cells expressing similar levels of WT human EGFR or EGFRC329R 
(Suppl. Figure S2c). Even though both BaF3/EGFR and BaF3/C329R cells responded to increasing doses of 
EGF, which induced cell growth in the absence of mIL-3, BaF3/C329R cells displayed hypersensitivity to the 
growth factor (Fig. 2a, EC50 BaF3/C329R 0.312 ± 0.082 ng/mL vs. BaF3/EGFR 0.732 ± 0.091 ng/mL, P < 0.05). 
Furthermore, this difference in sensitivity to low doses of EGF was associated with significantly increased output 
of viable BaF3/C329R cells over a 5 day period (Fig. 2b). Since we observed no difference in activation of caspases 
3 and 7 or in annexin V/7AAD staining (Suppl. Figure S5a,b) between these populations, the above results are 
consistent with the EGF-induced increase in cell numbers being predominantly from increased proliferation and 
not decreased apoptosis.
Analysis of signalling events associated with the mutant receptor in BaF3 and NIH3T3 cells revealed cell-type 
specific differences. In contrast to NIH3T3 cells, there was no significant increase in basal p-ERK1/2 in response 
to expression of the mutant receptor in BaF3 (Fig. 2c, Suppl. Figure S6d). In the presence of EGF (10 ng/mL), we 
observed phosphorylation of specific tyrosine residues selectively in the cells expressing WT receptor (Fig. 2c and 
Suppl. Figure S6a–c). In contrast, similar levels of p-AKTS473, p-ERK1/2T202/Y204 and p-STAT5Y694 were observed 
following EGF stimulation in both cells expressing EGFR WT or C329R (Fig. 2c and Suppl. Figure S6b–d). 
Treatment of the transduced cells with the selective EGFR inhibitor, gefitinib, blocked EGF-induced phospho-
rylation of EGFR, AKT, ERK1/2 and STAT5 in both EGFR WT and C329R expressing cells (Fig. 2c and Suppl. 
Figure S6a–d). STAT3 was not phosphorylated in the presence or absence of EGF treatment in BaF3/EGFR and 
BaF3/C329R cells (Suppl. Figure S6a). These results are consistent with an altered conformation of the EGFRC329R 
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dimer which may prevent receptor trans-phosphorylation of specific tyrosine residues in response to EGF stim-
ulation, but still permit downstream activation of signalling intermediates. Further investigations, including 
detailed determination of the dimer configuration and receptor phosphorylation on tyrosine, serine and threo-
nine residues, are needed to establish the mechanism by which the C329R mutation selectively affects signalling 
responses induced by EGF. Distinct signalling and functional differences have been described for different classes 
of EGFR mutations12 and it will be of interest to establish whether the signalling pattern that we identified is 
unique to EGFR extracellular mutants.
Expression of EGFRC329R in a haematopoietic cell line model of erythroid differentiation. The 
human TF1.8 cell line is an erythroleukaemic, GM-CSF-dependent cell line, which displays multi-lineage differ-
entiation potential. To investigate the effects of EGFR signalling on haematopoietic lineage, we transduced TF1.8 
cells with WT EGFR (TF1.8/EGFR), EGFRC329R (TF1.8/C329R) or vector alone (TF1.8/MIG), and confirmed that 
Figure 1. The EGFRC329R mutant induces colony formation, covalent receptor dimerization and altered 
signalling responses in NIH3T3 cells. (a) The affected cysteine residue 329 in EGFR (red dot) is highly 
conserved among species. *Indicates cysteine residues previously identified as mutated in solid tumours 
(COSMIC - Catalogue of Somatic Mutations in Cancer - v75 - http://cancer.sanger.ac.uk/cancergenome/
projects/cosmic/). (b) Anchorage-independent colony-forming potential was assessed in NIH3T3/MIG, 
NIH3T3/EGFR and NIH3T3/C329R with or without EGF (10 ng/mL). Bars represent mean ± SE of 3 
independent experiments performed in triplicate. T-test statistical analysis *P < 0.05, **P < 0.01, ***P < 0.001. 
(c) EGF-dependent and -independent covalent dimerization was determined in non-reducing and reducing 
western blot for total EGFR in lysates from NIH3T3/MIG, NIH3T3/EGFR and NIH3T3/C329R. Dimeric and 
monomeric species are indicated by arrows. These are cropped blots, full-length blots are presented in Suppl. 
Figure S3. (d) Western blot analysis of signalling responses in the presence or absence of serum (10% FCS and 
SF, respectively) in NIH3T3/MIG, NIH3T3/EGFR and NIH3T3/C329R lysates using indicated antibodies. 
These are cropped blots, full-length blots are presented in Suppl. Figure S4.
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TF1.8/EGFR and TF1.8/C329R expressed similar levels of receptor (Suppl. Figure S2d). We analysed myeloid/
erythroid differentiation by measuring surface expression of the granulocytic marker CD13, and the erythroid 
marker CD235a (glycophorin A). In the presence of GM-CSF, we observed a small increase in the percentage 
of CD235a-negative cells in TF1.8/C329R cells compared to TF1.8/EGFR and TF1.8/MIG, with no significant 
change in CD13 (Fig. 3a, gate a, 3b, top panel). This result is consistent with the mutant receptor signalling in the 
absence of exogenous EGF, and with such signalling being associated with a reduction in erythroid differentia-
tion. To explore this further, we cultured the TF1.8 transduced cells in EPO-containing medium, which induces 
an erythroid cell population defined by increased CD235a and reduced CD13 surface expression (Fig. 3a, gate c) 
at the expense of the CD235a-negative, CD13Hi population (Fig. 3a, gate a). The erythroid shift with EPO (gate a 
to gate c) was comparable for TF1.8/MIG and TF1.8/EGFR; however, this response was significantly reduced in 
the presence of EGFRC329R (Fig. 3a, EPO panels, gates a–c; Fig. 3b, panel EPO gate a). This observation suggests 
that signalling from the mutant receptor in the absence of exogenous EGF impairs EPO-induced differentiation. 
To examine the EGF response of the transduced TF1.8 cells, they were treated with two doses of EGF (0.5 ng/mL 
and 10 ng/mL). EGF-induced signalling suppressed erythroid differentiation as we observed a time-dependent 
increase in the CD235a-negative population (gate a) for both TF1.8/EGFR and TF1.8/C329R cells, but this 
increase was much more pronounced at the higher dose of EGF (Fig. 3a, EGF panels, Fig. 3b, bottom panel).
To investigate the mechanism by which EGFRC329R interferes with TF1.8 differentiation induced by EPO, we 
analysed EGFR signalling in these cells treated with GM-CSF or EGF (0.5 ng/mL and 10 ng/mL). We observed 
constitutive phosphorylation of tyrosine residues selectively in WT EGFR. EGF induced phosphorylation of both 
EGFR WT and C329R, with reduced levels of phosphorylation observed for C329R (Suppl. Figure S7a–c). We did 
not observe significant differences in signalling downstream from the receptors in any of the conditions tested 
(Suppl. Figure S7a–c). Overall these results are consistent with signalling from EGFRC329R limiting EPO-induced 
erythroid differentiation in the absence of exogenous EGF. The mechanism for the receptor-induced suppression 
of erythroid differentiation is unclear, although the phenotype resembles that reported for constitutive Ras signa-
ling which blocks Epo-induced erythroid differentiation of progenitors, and promotes Epo-independent prolifer-
ation of erythroblasts13. We note also that similar results have been observed in the same TF1.8 model following 
expression of a germline ERBB3 mutant (p. A1337T) identified in affected individuals from a family with MDS/
AML associated with erythroid hyperplasia14 (Suppl. Table S5).
Relationship of EGFRC329R and JAK2V617F in PV patient erythroid colonies. EGFR mRNA shows 
lineage-specific expression in haematopoietic cells from healthy individuals15, and is significantly upregulated in 
Figure 2. The EGFRC329R mutant increases sensitivity of BaF3 cells to EGF. (a) MTS assay was performed in 
BaF3/MIG, BaF3/EGFR and BaF3/C329R cells after 48 h of treatment with titrated concentrations of EGF 
(in the absence of mIL-3). For all treatments, cells were plated on day 0 at 105 cells/mL. Curves represent 
absorbance relative to no EGF. Points represent mean ± SE of 3 independent experiments. T-test *P < 0.05 
(C329R vs. EGFR). (b) MTS assay performed in BaF3/MIG, BaF3/EGFR and BaF3/C329R cells during 5 days 
of culture with low dose of EGF (0.5ng/ml). Curves represent absorbance relative to day 0, when cells were 
plated at 104 cells/mL. Points represent mean ± SE of 3 independent experiments. T-test *P < 0.05 (C329R vs. 
EGFR). (c) Western blot analysis of EGFR phosphorylation and downstream signalling in response to EGF (in 
the absence of mIL3), and to EGF inhibition by gefitinib, in BaF3/MIG, BaF3/EGFR and BaF3/C329R using 
indicated antibodies. These are cropped blots, full-length blots are presented in Suppl. Figure S6.
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MPN and AML patient samples16, 17. Therefore, we next analysed EGFR protein levels in healthy controls (HC) 
and PV patients. We detected, by flow cytometry, increased surface EGFR levels on BMMNC from three PV 
patients compared to HC (Suppl. Figure S8a), and for patient PV17 we could detect EGFR expression by Western 
blot using PBMNC lysate (Suppl. Figure S8b). These observations raise the possibility that EGFR protein level 
may be selectively increased in PV patients, contributing to growth and survival of the disease clone. To test 
this, we treated patient BMMNC with gefitinib (25 nM) and measured the formation of EPO–independent (i.e. 
Figure 3. The EGFRC329R mutant impairs erythroid differentiation in the human TF1.8 erythroleukemia cell 
line. (a) Dot plots representative of CD235a (glycophorin A, erythroid marker) and CD13 (myeloid marker) 
surface expression on TF1.8/MIG, TF1.8/EGFR and TF1.8/C329R cells on day 5 of culture with GM-CSF (5 ng/
mL), EPO (5 U/mL) or rhEGF (0.5 ng/mL or 10 ng/mL). (b) Percentage of cells in gates (a) or (c) (identified in 
(Fig. 3a) in GM-CSF culture (top panel), and plotted over a 7 day time-course for EPO (middle panels) or EGF 
(bottom panel) containing cultures. Points represent mean ± SE of 3 independent experiments. T-test *P < 0.05, 
**P < 0.01 (MIG vs. C329R). (c) Schematics of temporal acquisition of mutations (originating from a WT 
stem/progenitor cell) as determined from genotyping of individual BFU-E colonies plated from PBMNC. The 
percentage of each clone in PBMNC is shown.
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endogenous) BFU-E, which are characteristic of PV. As shown in Suppl. Figure S9, we observed inhibition of 
EPO-independent BFU-E, consistent with EGFR-signaling contributing to growth and survival of clonal cells 
derived from PV patients.
We next determined the clonal evolution of the disease in patient PV17 by genotyping of individual BFU-E 
grown from PBMNC. We determined EGFRC329R and JAK2V617F genotype using a quantitative single nucleo-
tide primer extension assay with mass array (Sequenom). As shown in Fig. 3c and Suppl. Table S4, we identi-
fied heterozygous JAK2V617F colonies that were WT for EGFR (13% of the total JAK2V617F-positive colonies), or 
heterozygous for EGFRC329R (5% of total JAK2V617F-positive), but no JAK2WT-EGFRC329R colonies were identi-
fied. BFU-E with JAK2 LOH were predominantly heterozygous for EGFRC329R (77% of total JAK2-mutant col-
onies). Thus, in this patient, it is likely that there was an initial JAK2V617F-heterozygous clone, and that LOH for 
JAK2V617F occurred secondarily in both JAK2V617F-single mutant (JAK2V617F-EGFRWT/WT) and double mutant 
(JAK2V617F-EGFRC329R/WT) derivatives (Fig. 3c). The dominance of the JAK2V617F-EGFRC329R/WT clone over the 
JAK2V617F-EGFRWT/WT clone suggests that the aberrant RTK activity associated with the EGFRC329R mutant pro-
vides a clonal advantage. A previous study in two PV patients with multiple LOH clones (identified by the extent 
of uniparental disomy) did not identify somatic mutations unique to the dominant clone which might have 
explained its dominance18. They concluded that stochastic processes determine which LOH clone predominates. 
The mechanism by which activated EGFR may cooperate with JAK2V617F signalling requires further study; none-
theless, a role in clonal expansion would be consistent with other studies indicating an important role for ERBB 
receptors in the expansion of progenitor cells (or “transit amplifying cells” in solid tumours) associated with 
de-differentiation and stem cell characteristics19. Such a mechanism may be a common driver of clonal amplifica-
tion and accumulation of additional mutations in tumours.
Role of aberrant ERBB, MET and ALK receptor signalling in MPN. While whole exome and tar-
geted sequencing of MPN sample cohorts have been undertaken by several groups, somatic mutations in EGFR 
have not previously been identified. We screened for recurrence of this EGFR mutation in our Australian MPN 
cohort (n = 160) using a custom Sequenom assay and did not identify any additional patients with this spe-
cific mutation. While mutations (most frequently in the tyrosine kinase domain) represent the most common 
EGFR-activating event in solid tumours (reviewed in ref. 20), it is possible that aberrant EGFR signalling also 
occurs via non-mutational mechanisms in MPN. Other reported mechanisms of oncogenic activation of EGFR 
include gene amplification, over-expression, and structural rearrangements (e.g. gene fusions) of the receptor, 
as well as tumour or stromal over-expression of EGF–family ligands (reviewed in ref. 20). Recently, an acquired 
mutation in MET (N375S) has been reported as recurrent in AML21.
Mutations affecting ERBB2 and ERBB3, or the related MET and ALK receptors, can result in activation of 
overlapping signalling responses. Two separate studies have suggested a functional role for HGF/MET in PV22, 23, 
and a previous exome sequencing study of MPN patient samples identified acquired mutations in MET (V1247A, 
adjacent to the somatic mutation identified in our screen) and in ERBB2 (L494F)24. Overall, mutations in ERBB 
receptors, MET and ALK are rare in MPN (those described to date are summarized in Suppl. Table S5); however, 
recurrent mutations in genes that affect the signalling of this group of receptors (e.g. CBL and RAS) have been 
reported in MPN2, 24.
In summary, the characterization of the novel extracellular EGFRC329R mutation has revealed a potential role 
for increased RTK signalling in parallel with, but independent of, JAK2 in MPN. Cross-talk between JAK2 and 
EGFR oncogenic signalling has recently been reported in lung adenocarcinoma where JAK2 activity has been 
shown to promote receptor turnover via the ubiquitin-mediated degradation pathway25. Since EGFR has been 
shown to promote HSC survival under conditions of increased HSC proliferation26, we speculate that in the 
context of aberrant JAK2 activity in HSPC there may be a requirement for mechanisms that activate or sensitize 
RTK signalling. Aberrant activation of signalling pathways by JAK2-independent mechanisms may also provide 
an explanation for the observed resistance of MPNs to JAK inhibitor therapy, which commonly has limited effect 
on JAK2 allelic burden, even in patients with a positive clinical response27. Furthermore, as inhibition of JAK2 has 
been shown to increase abundance of EGFR on the cell surface25, this raises the possibility that combining JAK2 
inhibitors with EGFR and/or MEK inhibition may be an effective strategy in selected MPN patients where the 
aim of treatment is to reduce the disease-initiating clone. Such a dual-targeting approach has been reported to be 
effective in lung cancer patients resistant to EGFR inhibition28.
Material and Methods
MPN Patients. MPN patients (92 PV, 39 ET, 17 MF, and 12 unclassified MPN) were recruited from 3 major 
South Australian hospitals (The Royal Adelaide Hospital – RAH, The Queen Elizabeth Hospital – TQEH, and 
Flinders Medical Centre – FMC). Clinical information and samples were collected for research with informed 
consent from all subjects, and with approval from the following Human Research Ethics Committees (HREC): 
RAH HREC, TQEH HREC, FMC HREC, and University of South Australia HREC. All experiments were per-
formed in accordance with relevant guidelines and regulations with approval from the RAH and University of 
South Australia HREC.
Exon capture sequencing. Genomic DNA was prepared from granulocyte or peripheral blood mono-
nuclear cells (PBMNC) from 15 PV patients (all confirmed positive for JAK2V617F) and used in an initial exon 
capture experiment. 657 cancer-related genes were captured (Suppl. Table S1), including genes with mutations 
in COSMIC (v48) and genes involved in AML, CML, ALL, CLL and lymphoma, using NimbleGen solid phase 
capture (2009) on genome build hg18 (Roche-NimbleGen). For capture, the 15 DNA samples were combined 
into 5 pools without barcoding (Suppl. Table S2). Captured DNA was sequenced on a SOLiD (3.5) platform and 
base calling and alignment performed using SOLiD™ BioScope™ software 1.3 (Applied Biosystems). A total of 
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8 958 exons were captured and 88.3% of these produced efficient sequence. SeattleSeq Annotation was used to 
annotate sequence variants. To generate the list of variants in Suppl. Table S3 we filtered for exonic Tier 1 variants 
and removed variants that were present in 1000 genomes or ExAC database. For the ESP database we filtered to 
remove variants with a frequency in the Caucasian population of >1%. Finally, variants with variant allele fre-
quency (VAF) of between 6% and 32% in any pool were included, and all variants that were present at a frequency 
of >5% across all pools were excluded. For variants of interest we used Sanger sequencing of matched granulocyte 
and buccal DNA to determine the affected patient within the pool, and germline/somatic status.
Haematopoietic cell lines. The murine BaF3 cell line was cultured as previously described29. The human 
TF-1.8 cell line30 was cultured in recombinant human GM-CSF (5 ng/mL; Peprotech, Rocky Hill, NJ, USA) as 
described31.
EGFR retroviral expression constructs. The complete EGFR ORF was obtained from the EST Image 
Clone 4483665 (ThermoFisher Scientific, Waltham, MA, USA). EGFR was cloned into the retroviral vector, 
pMSCV-IRES-eGFP (MIG)32 and the C329R mutation introduced using the Phusion Site-directed Mutagenesis 
kit (ThermoFisher Scientific). Retroviral transduction of cell lines was performed as previously described32. Cells 
were sorted for eGFP expression with a BD FACSAria II (BD Biosciences, Franklin Lakes, NJ, USA).
Caspase activity, viability and proliferation assays. To measure growth and survival of BaF3 cell pop-
ulations expressing EGFR WT or EGFRC329R, cells were washed 3 times with PBS and incubated with growth 
factor (mIL-3 or rhEGF; R&D Systems, Minneapolis, MN, USA) at the indicated doses. Cell growth was assessed 
using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI, USA) 
following the manufacturer’s instructions. Caspase activity was measured with Caspase-Glo 3/7 Assay (Promega) 
as per the manufacturer’s instructions. Viability was measured by Annexin V (BD Biosciences) and 7AAD (BD 
Biosciences) staining, following the manufacturer’s protocol.
Soft-agar colony formation. Colony formation assay with NIH3T3 transduced cells was conducted as 
described33 using a 6-well format.
Flow cytometry analysis. For EGFR detection, 106 cells were fixed with 1.6% formaldehyde 
(Sigma-Aldrich, St. Louis, MO, USA) for 10 min at room temperature (RT), pelleted and washed with PBS twice. 
For total EGFR expression, cells were permeabilised with 80% ethanol for 20 min on ice followed by two washes 
with PBS. For total or surface EGFR expression, cells were then washed with 1% BSA (Sigma-Aldrich) in PBS, 
and finally pelleted and re-suspended in 100 µL of anti-EGFR antibody (clone D38B1, cat #4267, Cell Signaling 
Technology, Danvers, MA, USA) diluted in 1% BSA in PBS. Incubation was for 1 hour at RT followed by one 
wash with PBS. Cells were then re-suspended in 100 µL of anti-rabbit Alexa Fluor® 647 conjugate secondary 
antibody (cat #4414, Cell Signaling Technology) diluted in 1% BSA in PBS and incubated for 30 min at RT in 
the dark. Finally, cells were washed twice with PBS, re-suspended in 250 µL of PBS and analysed on a GalliosTM 
Flow Cytometer (Beckman Coulter, Brea, CA, USA). For detection of erythroid differentiation surface markers 
in TF1.8 transduced cell populations, staining was performed as above with the following antibodies: BV421 
mouse anti-human CD235a (clone GA-R2-HIR2, cat #562938, BD Biosciences) and PE anti-human CD13 (clone 
WM15, cat #301704, BioLegend, San Diego, CA, USA). Detection was performed on a BD LSRFortessa (BD 
Biosciences). Flow cytometry data were analysed with FCS Express4 Flow Research Edition (DeNovo Software, 
Glendale, CA, USA).
Western blotting. For analysis of signalling responses and EGFR dimer, cells were washed with PBS contain-
ing 10 mM iodoacetamide (Sigma-Aldrich) and then lysed with NP40 Cell Lysis Buffer (ThermoFisher Scientific) 
containing cOmplete Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany), PhosStop (Roche 
Diagnostics), Pefabloc (Roche Diagnostics) and iodoacetamide (Sigma-Aldrich). Western blot was performed as 
described32. Primary antibodies used were: EGFR (clone 15F8, cat #4405, to detect EGFR dimer), EGFR (clone 
D38B1, cat #4267), p-EGFR Tyr845 (clone D63B4, cat #6963), p-EGFR Tyr992 (cat #2235), p-EGFR Tyr1068 
(clone D7A5, cat #3777), p44/42 MAPK (cat #9102), p-p44/42 MAPK Thr202/Tyr204 (cat #9101), STAT5 
(clone 3H7, cat #9358), p-STAT5 Tyr694 (cat #9351), STAT3 (clone 79D7, cat #4904), p-STAT3 Tyr705 (clone 
D3A7, cat #9145), AKT (cat #9272) and p-AKT Ser473 (cat #9271), all from Cell Signaling Technology, and 
anti-tubulin (clone E-19, sc-12462-R, Santa Cruz Biotechnology, Dallas, TX, USA). Secondary antibody used 
was anti-rabbit-AP conjugate (Santa Cruz Biotechnology). Total protein levels were determined after stripping 
the blots probed with the phosphoprotein antibody and re-probing with respective total protein antibody. Tubulin 
was used as loading control; blots were stripped after probing with total protein antibody and re-probed with 
anti-tubulin antibody. Blots were imaged using the Typhoon FLA 9000 (GE Healthcare Life Sciences, Uppsala, 
Sweden) and images analysed using ImageQuant TL (GE Healthcare Life Sciences).
Genotyping for EGFRC329R and JAK2V617F. We used previously established methods based on Sequenom 
mass array34 for sensitive detection of EGFRC329R and JAK2V617F mutations. A multiplex assay was designed and 
performed on PBMNC or granulocyte DNA from a cohort of 160 MPN patients with clinical diagnosis of PV 
(n = 92); ET (n = 39); MF (primary or post-PV/post-ET; n = 17); or uncharacterized MPN (n = 12).
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